How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?
Maintenance treatment has been used for several years inside clinical trials. Meta-analyses have been published. A new clinical trial (AVAPERL) has been recently published. Despite significant increase of progression-free survival (PFS), overall survival (OS) has not been changed with these strategies. Before a transfer into clinical practices and guidelines, new data on economic analyses (the cost effectiveness ratio was very high among specific studies) and quality of life are mandatory.